RxDoctor Payments Data

David Schwartz

Pulmonary Disease · Aurora, CONPI 1790869675

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $470,933 of the $471,100 with a category attached, or 100.0%. Vertex accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2021 at $137,500 and has fallen 100.0% since, to $22 in 2023. Among pulmonary disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$471,100in general payments, 2019–2025

Across 55 payments — averaging $8565.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$471K
  • AstraZeneca$22
$6,251,573in research payments, 2019–2025

Across 5 payments — averaging $1,250,315 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$6.3M

What the payments were for

  • Consulting fees$470,933100%
  • Food & beverage$1670%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex54$471,078
AstraZeneca1$22

How this compares

$471,100 in reported general payments places this provider in the 95th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Other pulmonary disease in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →